Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Gastric cancer is a leading cause of cancer mortality with poor survival rates.
• Existing chemotherapies show limited efficacy against stomach cancer.
• Triptolide and its pro-drug Minnelide were investigated for their anti-cancer effects.

Purpose of the Study:

• To evaluate the efficacy of triptolide and Minnelide as monotherapy and in combination with CPT-11 against gastric adenocarcinoma.
• To assess the impact of these agents on gastric cancer cell viability, apoptosis, and tumor growth in preclinical models.

Main Methods:

• In vitro treatment of gastric cancer cell lines (MKN28, MKN45) with triptolide.
• Assessment of cell viability using MTT assay and apoptosis via caspase activity.
• In vivo evaluation of Minnelide in athymic nude mice xenograft models, including combination therapy with CPT-11.

Main Results:

• Triptolide treatment decreased cell viability and increased apoptosis in gastric cancer cell lines.
• Minnelide administration reduced tumor burden in both MKN28 and MKN45 xenograft models.
• Combination therapy of Minnelide and CPT-11 demonstrated significant tumor reduction in the NCI-N87 model.

Conclusions:

• Minnelide, particularly in combination with CPT-11, shows significant potential for gastric cancer treatment.
• These findings support the ongoing clinical trials of Minnelide for gastrointestinal cancers.